首页> 美国卫生研究院文献>Springer Open Choice >Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma

【2h】

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma

机译：抗GM2神经节苷脂单克隆抗体BIW-8962在先前治疗的多发性骨髓瘤患者中作为单一疗法的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionBIW-8962 is a monoclonal antibody to GM2 ganglioside that shows preclinical activity towards multiple myeloma (MM) cell lines and in animal models bearing MM xenografts. The objective of this study was to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, potential immunogenicity, and preliminary clinical efficacy of BIW-8962 in patients with heavily pretreated MM.

机译：简介BIW-8962是抗GM2神经节苷脂的单克隆抗体，对多发性骨髓瘤（MM）细胞系以及带有MM异种移植物的动物模型显示出临床前活性。这项研究的目的是确定BIW-8962在严重预处理的MM患者中的安全性，耐受性，最大耐受剂量（MTD），药代动力学，潜在的免疫原性和初步临床疗效。

著录项

期刊名称 Springer Open Choice
作者
Rachid C. Baz; Jeffrey A. Zonder; Cristina Gasparetto; Frederic J. Reu; Vincent Strout;
展开▼
作者单位

展开▼
年(卷),期 -1(4),2
年度 -1
页码 287–301
总页数 15
原文格式 PDF
正文语种
中图分类外科学;
关键词
BIW-8962 Anti-GM2 ganglioside monoclonal antibody Phase I trial Safety Multiple myeloma;

机译：BIW-8962;抗GM2神经节苷脂单克隆抗体;I期试验;安全性;多发性骨髓瘤;

相似文献

外文文献
中文文献
专利

1. Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma [J] . Rachid C. Baz, Jeffrey A. Zonder, Cristina Gasparetto, Oncology and Therapy . 2016,第2期

机译：抗GM2神经节苷脂单克隆抗体BIW-8962在先前治疗的多发性骨髓瘤患者中作为单一疗法的I期研究
2. P1.01-070 BIW-8962, an Anti-GM2 Ganglioside Monoclonal Antibody, in Advanced/Recurrent Lung Cancer: A Phase I/II Study [J] . J. Lee, J. Kim, S. Kim, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P1.01-070 BIW-8962，抗GM2神经节苷脂单克隆抗体，高级/复发性肺癌：I / II期研究
3. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma [J] . KaufmanJ.L., NiesvizkyR., StadtmauerE.A., British Journal of Haematology . 2013,第4期

机译：在复发或难治性多发性骨髓瘤中使用米拉妥珠单抗（人源化抗CD74单克隆抗体）单药治疗的I期多中心剂量递增试验
4. Comparative Proteomic Study of Mechanisms Involved in the Expression of Recombinant Monoclonal Antibody in Non Amplified NSO Myeloma Cell Line [C] . Luis E. Rojas, Kathya R. de la Luz Hernandez, Svieta Victores, General Meeting of European Society of Animal Cell Technology . 2007

机译：对非扩增NSO骨髓瘤细胞系重组单克隆抗体表达的机制的比较蛋白质组学研究
5. Evaluation of the Protection Induced by a Monotherapy of Anti-LFA-1 Monoclonal Antibody and Co-transplantation of Neonatal Porcine Islets with Sertoli Cells. [D] . Bayrack, Kevin. 2012

机译：评估抗LFA-1单克隆抗体的单药治疗和新生猪胰岛与支持细胞共移植的保护作用。
6. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma [O] . Mohamad Hussein, James R. Berenson, Ruben Niesvizky, 2010

机译：多发性骨髓瘤患者中dacetuzumab（SGN-40;人源化抗CD40单克隆抗体）的I期多剂量研究
7. Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma [O] . Rachid C. Baz, Jeffrey A. Zonder, Cristina Gasparetto, 2016

机译：抗GM2神经节苷脂单克隆抗体BIW-8962在先前治疗的多发性骨髓瘤患者中作为单一疗法的I期研究

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅